News Conference News ESC 2025 HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients Caitlin E. Cox September 01, 2025
News Conference News ACC 2025 Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT Caitlin E. Cox March 29, 2025
News Conference News VIVA 2024 DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years L.A. McKeown November 11, 2024
News Conference News TCT 2024 PEERLESS: FlowTriever Tops Catheter-Directed Thrombolysis for Acute PE Todd Neale October 29, 2024
News Conference News ISET 2024 AI in Pulmonary Embolism: ‘Transformative’ for Patient Care Caitlin E. Cox January 30, 2024
News Conference News ISET 2024 Venous Stents: How to Choose Among the Wealth of Options Caitlin E. Cox January 26, 2024
News Conference News ESC 2022 DANCAVAS: Food for Thought as CV Screening in Older Men Misses Mark L.A. McKeown August 30, 2022
News Conference News TCT 2020 Interventionalists, Including PERTs, Grapple With VTE Risks of COVID-19 Michael O'Riordan October 14, 2020
News Conference News ACC 2020 Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients L.A. McKeown April 01, 2020
News Conference News VIVA 2019 Future Pulmonary Embolism Interventions: Wild West or Working Together? L.A. McKeown November 14, 2019
News Conference News ESC 2019 ESC Updates Guidance on Management of Acute Pulmonary Embolism Todd Neale September 06, 2019
News Conference News ISET 2019 Vici Venous Stent Shows Good Primary Patency, Few MAE by 12 Months: VIRTUS Caitlin E. Cox February 08, 2019
News Conference News ESC 2018 MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis Todd Neale August 26, 2018